# Patient Blood Management Market > Patient Blood Management Market Research Report Information By Product (Instruments, Accessories, Reagents and Kits, Software), By Component (Whole Blood, Plasma), By End-User (Blood Banks, Hospitals, Diagnostic Clinics, Pathology Labs), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 6.27% - **2024:** $ 8.61 Billion - **2025:** $ 9.15 Billion - **2035:** $ 16.81 Billion - **Key Players:** Haemonetics (US), Terumo Corporation (JP), Fresenius Kabi (DE), Grifols (ES), Baxter International (US), Cerus Corporation (US), BloodCenter of Wisconsin (US), Octapharma (CH), Medtronic (US) **Report ID:** MRFR/HC/7326-HCR · **Pages:** 112 · **Author:** Vikita Thakur & Kinjoll Dey · **Last Updated:** May 28, 2026 **URL:** https://www.marketresearchfuture.com/reports/patient-blood-management-market-8798 --- ## Market Summary ## **Patient Blood Management Market Overview** Patient Blood Management Market Size was valued at USD 8.04 billion in 2023. The patient blood management market industry is projected to grow from USD 8.61 Billion in 2024 to USD 14.022 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.27% during the forecast period (2024 - 2032). The main market drivers for the patient blood management market include the growing recognition of the importance of donated blood from the many sectors of the healthcare infrastructure, life sciences, placenta research, and hemoglobin for the development of the medical industry.  Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review The development of the medical industry is one of the primary market drivers for the patient blood management market. The rising demand for patient blood management is attributable to the global increase in the number of ailing individuals. The demand for patient blood management products increases as the population ages and becomes more prone to anaemia and blood requirements. Due to technological advancements, the designs of these devices have vastly improved, which has increased patient preference for patient blood management products. Thus driving market revenue for patient blood management. In addition, malignancies that originate in the bone marrow (such as leukemias) or that have spread there from other sites may cause low blood counts by accumulating normal blood-forming cells. Therefore, the rise in blood cancer incidence promotes the expansion of the patient blood management market. In addition, the rise in government spending on healthcare drives the establishment of new blood banks, diagnostic clinics, pathology laboratories, and government hospitals, which has led to the widespread adoption of patient blood management products and fueled the expansion of this market. July 2023: Quanterix Corporation, a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, announced in July 2023 the launch of LucentAD, a test designed to aid in the evaluation of patients exhibiting cognitive symptoms consistent with the earliest stages of Alzheimer's disease (AD). The LucentAD test, which will be available to healthcare providers in conjunction with other diagnostic tools, enables clinicians to assess a patient's likelihood of having amyloid pathology consistent with AD in a streamlined manner. This information will assist healthcare professionals in determining the appropriate follow-up and treatment planning for a patient suspected of having Alzheimer's. In June 2023, Kakao Corporation's digital healthcare business entered into a collaborative deal with Dexcom to provide a worldwide digital diabetes management service. The agreement, as stated in a press release, merges Kakao Healthcare's expertise in artificial intelligence (AI) and software technology with Dexcom's continuous glucose monitoring (CGM) devices, specifically the Dexcom G6 and G7. Dexcom is currently in the process of seeking approval from the Ministry of Food and Drug Safety for these devices. In November 2022, Eli Lilly and Company declared their plans to introduce the Tempo® Personalized Diabetes Management Platform in the United States later this year. This platform will be the company's first linked platform. The system aims to aid persons diagnosed with either type 1 or type 2 diabetes, as well as professionals, in making well-informed decisions based on data when it comes to managing Lilly insulin medication. The collaborative development of the compatible app involved Welldoc® and resulted in a private label version of BlueStar®, the diabetes management app owned by the firm. This customized version of the app is capable of receiving insulin dose-related data from the Tempo Smart Button. Healthcare providers will be able to utilize Tempo InsightsTM, a clinician portal, to access data that patients have contributed through the app and track patients' advancements. ## **Patient Blood Management Market Trends** The market CAGR for patient blood management grew as a result of an increase in accidents, trauma cases, and surgical procedures. WHO estimates that 1.35 million people worldwide lose their lives in traffic accidents every year, with 93% of these deaths occurring in low- and middle-income nations. According to the Centers for Disease Control and Prevention, the caesarean birth rate was 32.1% of all births in 2021. The patient blood management market is being driven by an increase in accidents, trauma cases, and surgical procedures that have led to an increase in the need for blood and its products. Additionally, an increase in blood donations and donors is anticipated to fuel market revenue growth. For instance, in the U.S., a daily requirement of about 29,000 units of red blood cells is required. Each year, around 16 million different blood components are transfused. More than 1.8 million people are diagnosed with cancer in 2020, and many of them will need blood transfusions during their chemotherapy treatments—some even daily. PBM incorporates all aspects of the transfusion decision-making process, from the first patient evaluation to clinical therapy, and is an evidence-based approach to treating patients who require blood transfusions. The increase in the number of ill people in the world is the cause of the rising demand for patient blood management. The demand for patient blood management products rises as the population gets older and is more susceptible to anaemia and blood needs. For instance, according to a report from UNFPA Asia-Pacific, it is predicted that the region's older population will triple to 1.3 billion by 2050, with women making up the majority (53 percent) of those in the region who are 60 or older and the majority (60 percent) of those over 80. The designs of these devices have significantly improved thanks to technical breakthroughs, which has increased patient preference for patient blood management goods. Thus, driving the patient blood management market revenue. ## **Patient Blood Management Market Segment Insights** ### **Patient Blood Management Product Insights** The patient blood management market segmentation, based on product includes Instruments, Accessories, Reagents and Kits, and Software. The instruments segment dominated the market due to a growth in the need for blood after surgery, an increase in the number of trauma cases, numerous government organizations regulating blood banks, and an increase in trauma cases. Furthermore, due to the increased use of reagents and kits, growth in bloodstream infection, and rise in sepsis incidence, the reagents and kits segment is anticipated to experience the highest CAGR. ### **Patient Blood Management Component Insights** The patient blood management market segmentation, based on component, includes Whole Blood and Plasma. The whole blood category generated the most income due to the increased demand for blood, accidents, illnesses like anaemia, haemophilia, blood clots, and blood cancers like leukemia and lymphoma. Besides, due to the growth in liver illnesses among the senior population, which call for the usage of plasma globally, the plasma segment is anticipated to experience the greatest growth rate throughout the forecast period. **Figure 1: Patient Blood Management Market, by Component, 2023 & 2032 (USD billion)**  _Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review_ ### **Patient Blood Management End-User Insights** The patient blood management market segmentation, based on end-user, includes Blood Banks, Hospitals, Diagnostic Clinics and Pathology Labs. The blood banks category generated the most income. Blood banks are strictly regulated, ensuring donors can safely donate their blood or plasma. This segment's revenue growth is also being influenced by rising awareness of blood donation. ### **Patient Blood Management Regional Insights** By Region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The Asia Pacific patient blood management market will dominate due to expanding demand for blood transfusions, rising rates of iron deficiency in the population, and considerable government efforts to raise public awareness of safe blood transfusion practices while updating current infrastructure. For instance, after realizing the importance of blood in sustaining the nation's healthcare system, the Indian government launched a variety of programmes. One of these steps was the creation of the National Blood Transfusion Council, which ensures coordination between the states, other ministries, and health initiatives. Further, the major countries studied in the market report are The U.S., Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil. **Figure 2: PATIENT BLOOD MANAGEMENT MARKET SHARE BY REGION 2023 (%)**  _Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review_ Europe patient blood management market accounts for the second-largest market share. This is due to technological advances that make it possible to create unusual blood types in the lab and the rising prevalence of target disorders like anaemia. For instance, 25% of the world's population, or about 1.6 billion people, have anaemia. Preoperative anaemia is a common side effect of major surgery. Traditional treatments, such blood transfusions, have a number of disadvantages. Patient blood management aims to increase market income by reducing the need for transfusions. Further, the German patient blood management market held the largest market share, and the UK patient blood management market was the fastest growing market in the European region The North America Patient blood management Market is expected to grow at the fastest CAGR from 2023 to 2032 due to a rise in the population's iron deficiency, a rise in the need for blood transfusions, and major government efforts to raise knowledge of safe blood transfusion practices while also updating the country's infrastructure. For instance, the Indian government launched several initiatives after realizing the significance of blood in the nation's healthcare system. As one of these steps to ensure collaboration between the states, several ministries, and health programmes, the National Blood Transfusion Council was founded. Moreover, US patient blood management market held the largest market share, and the Canada patient blood management market was the fastest growing market in the Asia-Pacific region. ### **Patient Blood Management Key Market Players & Competitive Insights** Leading market players are investing heavily in research and development in order to expand their product lines, which will help the patient blood management market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, patient blood management industry must offer cost-effective items. Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the patient blood management industry to benefit clients and increase the market sector. In recent years, the patient blood management industry has offered some of the most significant advantages to medicine. Major players in the patient blood management market attempting to increase market demand by investing in research and development operations include Biomérieux SA_, _Bio-Rad Laboratories Inc., Braun Melsungen AG_, _Abbott Laboratories_,_ Danaher Corporation_, _Hitachi Ltd and Terumo Corporation. Medical technology and pharmaceutical goods are developed, produced, and distributed by B. Braun Melsungen AG (B. Braun), in addition to offering medical services. Infusion solutions and consumables, infusion pumps and systems, cleaning products, nutrition and pain management, hip and knee implants, suture materials, surgical instruments, ostomy care, dialysis equipment and accessories, and wound care products are some of the company's main offerings. In the areas of anaesthesia, extracorporeal blood transfusion, intensive care, cardiology, and surgery, B. Braun offers goods and systems.In 2018, the bloodlines division of NxStage Medical, Inc. (US), which operates under the Medisystems name, was purchased by B. Braun Melsungen AG (Ireland). Danaher Corp. (Danaher) develops, produces, and sells goods and services for the industrial, commercial, professional, and medical industries. A wide range of testing equipment, communications solutions, water quality systems, professional microscopes, product identification solutions, automation solutions, medical diagnostic solutions, sustainable packaging design solutions, life science research tools, and sensors and controls solutions are available. The corporation runs manufacturing, sales, distribution, service, and administrative facilities across Europe, Australia, Asia, and the Americas. June 2023: Kakao Corporation's digital healthcare division has engaged into a collaboration agreement with Dexcom to establish a global digital diabetes management service in June 2023. The agreement combines, according to a press release, Kakao Healthcare's capabilities in artificial intelligence (AI) and software technology with Dexcom's continuous glucose monitoring (CGM) devices, the Dexcom G6 and G7, for which the company is presently seeking approval from the Ministry of Food and Drug Safety. November 2022: Eli Lilly and Company announced in November 2022 that it will launch its first connected platform, the Tempo® Personalized Diabetes Management Platform, in the United States later this year. The technology seeks to assist adults with type 1 or type 2 diabetes and clinicians in making informed, data-supported decisions regarding the management of Lilly insulin treatment. The compatible app was developed in collaboration with Welldoc® and is a private label version of BlueStar®, the company's diabetes management app, modified to receive insulin dose-related data from the Tempo Smart Button. Healthcare providers will have access to Tempo InsightsTM, a clinician portal where they can access data shared by patients via the app and monitor patients' progress.  ### **Key Companies in the patient blood management market include** ## **Patient Blood Management Industry Developments** _**September 2022:**__A long-term agreement was inked by Canadian Blood Services, Canada's national blood authority, and Grifols, a major participant in the world of plasma pharmaceuticals. This arrangement would enable the company to greatly boost Canada's self-sufficiency in immunoglobulin (Ig) medications, important plasma-protein therapies used to treat a variety of immunodeficiencies as well as other health issues._ _**April 2022:**__In order to do additional research on freeze-dried plasma (FDP), Terumo Blood and Cell Technologies was given a contract worth USD 10.6 million. The Defense Health Agency (DHA) sponsors the contract, which is managed by the Naval Medical Research Centre (NMRC). It is with MTEC, a 501(c)(3) biomedical technology consortium that collaborates with the U.S. Army Medical Research and Development Command under an Other Transaction Agreement (OTA)._ ## **Patient Blood Management Market Segmentation** ### **Patient Blood Management Product Outlook** ### **Patient Blood Management Component Outlook** ### **Patient Blood Management End-User Outlook** ### **Patient Blood Management Regional Outlook** **North America** **Europe** **Asia-Pacific** **Rest of the World** -   -   -   -   -   - Beta Beta feature -   -   -   -   -   - Beta Beta feature ## Market Drivers ### Regulatory Support and Compliance Regulatory frameworks and guidelines established by health authorities are instrumental in driving the Patient Blood Management Market. These regulations often mandate the implementation of standardized blood management practices to ensure patient safety and improve clinical outcomes. For example, organizations such as the World Health Organization and various national health agencies advocate for the adoption of patient blood management protocols.   Compliance with these regulations not only enhances patient care but also mitigates legal risks for healthcare providers. As a result, hospitals are increasingly investing in training and resources to align with these guidelines, thereby fostering the growth of the Patient Blood Management Market. The ongoing evolution of regulatory requirements is expected to further stimulate advancements in blood management practices. ### Growing Awareness of Patient Safety The heightened awareness surrounding patient safety and quality of care is a significant driver for the Patient Blood Management Market. Healthcare institutions are increasingly prioritizing strategies that minimize the risks associated with blood transfusions, such as transfusion-related infections and adverse reactions. This shift is reflected in the implementation of evidence-based guidelines and protocols aimed at optimizing blood use.   Studies indicate that effective patient blood management can reduce transfusion rates by up to 30%, thereby enhancing patient safety and reducing healthcare costs. As hospitals and clinics strive to meet regulatory standards and improve patient outcomes, the focus on patient blood management is likely to gain momentum, further propelling the growth of the Patient Blood Management Market. ### Increasing Prevalence of Chronic Diseases The rising incidence of chronic diseases such as cardiovascular disorders, diabetes, and cancer is a pivotal driver for the Patient Blood Management Market. These conditions often necessitate frequent blood transfusions and surgical interventions, thereby increasing the demand for effective blood management strategies. According to recent data, approximately 60% of patients undergoing major surgeries require blood transfusions, highlighting the critical need for robust blood management systems.   As healthcare providers strive to enhance patient outcomes and minimize complications associated with blood transfusions, the focus on patient blood management becomes increasingly pronounced. This trend is likely to propel the growth of the Patient Blood Management Market, as hospitals and clinics invest in advanced technologies and protocols to optimize blood usage and improve patient safety. ### Technological Innovations in Blood Management Technological advancements play a crucial role in shaping the Patient Blood Management Market. Innovations such as automated blood collection systems, advanced blood screening technologies, and data analytics tools are transforming how healthcare providers manage blood resources. For instance, the integration of artificial intelligence in blood management systems allows for real-time monitoring and predictive analytics, which can significantly reduce wastage and enhance transfusion safety.   The market for blood management technologies is projected to grow at a compound annual growth rate of over 10% in the coming years, driven by the increasing adoption of these innovative solutions. As healthcare facilities seek to improve operational efficiency and patient outcomes, the emphasis on adopting cutting-edge technologies in the Patient Blood Management Market is expected to intensify. ### Rising Demand for Cost-Effective Healthcare Solutions The escalating need for cost-effective healthcare solutions is a driving force behind the Patient Blood Management Market. As healthcare costs continue to rise, providers are under pressure to implement strategies that enhance efficiency while maintaining high-quality care. Patient blood management initiatives have been shown to reduce unnecessary transfusions, thereby lowering associated costs.   Research indicates that effective blood management can save healthcare systems millions annually by minimizing transfusion-related complications and optimizing blood utilization. This financial incentive is prompting healthcare facilities to adopt comprehensive blood management programs, which in turn is likely to fuel the growth of the Patient Blood Management Market. As the focus on value-based care intensifies, the demand for innovative and cost-effective blood management solutions is expected to increase. ## Future Outlook The Patient Blood Management Industry is projected to grow at a 6.27% CAGR from 2025 to 2035, driven by technological advancements, increasing awareness, and regulatory support. **New opportunities:** - Integration of AI-driven analytics for patient blood utilization Development of mobile blood management applications Expansion of partnerships with healthcare providers for blood conservation programs By 2035, the Patient Blood Management Industry is expected to be robust, driven by innovation and strategic collaborations. ## Segment Insights ### By Product: Instruments (Largest) vs. Accessories (Fastest-Growing) In the Patient Blood Management Market, the 'Instruments' segment holds the largest market share, driven by their essential role in blood collection, processing, and transfusion. Key instruments such as blood bags, separator machines, and transfusion devices are critical for effective blood management in healthcare settings. In contrast, the 'Accessories' segment, including various disposable products and supportive tools, is witnessing the fastest growth as hospitals and clinics increasingly prioritize safety and efficiency in blood handling processes. Instruments (Dominant) vs. Accessories (Emerging) The 'Instruments' segment is characterized by robust demand owing to its foundational role in the Patient Blood Management Market ecosystem. Key players are focusing on innovation to enhance functionality and integrate advanced technologies into their devices. Meanwhile, 'Accessories', which encompass crucial components such as blood collection tubes and sterilization equipment, represent an emerging market trend. Their rapid adoption reflects a shift toward comprehensive blood management protocols that prioritize patient safety and operational efficiency. As healthcare providers seek to streamline blood management systems, both segments are critical in shaping the future landscape of patient care in transfusion medicine. ### By Component: Whole Blood (Largest) vs. Plasma (Fastest-Growing) In the Patient Blood Management Market, the Whole Blood segment holds a significant share, reflecting its established role in transfusion practices and surgical procedures. This component is generally viewed as the foundational element in blood management, catering effectively to high demand, particularly in trauma and emergency care settings. Its market share continues to be substantial due to the increasing necessity for blood products, especially amidst rising road accidents and surgical interventions. Whole Blood: Dominant vs. Plasma: Emerging The Whole Blood segment is recognized as the dominant force within the Patient Blood Management Market, attributed to its versatility and crucial application across various medical scenarios. It is particularly favored in trauma care, where immediate transfusion is often required. Conversely, the Plasma segment is emerging as a significant player, driven by innovations in therapies and an increasing understanding of plasma's potential in treatments, such as clotting disorders and immune therapies. This emerging segment is experiencing rapid growth, fueled by advances in processing technologies and heightened awareness of plasma's benefits in numerous medical applications. ### By End-User: Hospitals (Largest) vs. Blood Banks (Fastest-Growing) In the Patient Blood Management Market, hospitals represent the largest segment, commanding a significant share due to their critical role in managing patient blood supplies and ensuring safe transfusions. Blood banks follow closely, providing essential services for blood donation, storage, and distribution, serving as vital partners to hospitals. Diagnostic clinics and pathology labs, while smaller players, also contribute to this industry by ensuring blood compatibility and conducting necessary tests for transfusions, though their market share remains relatively minor compared to hospitals and blood banks. Blood Banks (Emerging) vs. Hospitals (Dominant) Hospitals dominate the Patient Blood Management Market as they account for the majority of blood usage and therefore are pivotal in blood management processes. They integrate blood management protocols into their operations to enhance patient safety, reduce wastage, and optimize blood utilization. On the other hand, blood banks are an emerging force, experiencing rapid growth as the demand for stored blood increases and public awareness about blood donation rises. They are adapting technologically by implementing advanced blood tracking systems and improving storage solutions to cater to the escalating needs, effectively establishing their place in the market. ## Regional Market Share Analysis ### North America : Market Leader in Innovation North America is the largest market for Patient Blood Management Market, holding approximately 45% of the global share. The region benefits from advanced healthcare infrastructure, high demand for blood management solutions, and supportive regulatory frameworks. The increasing prevalence of chronic diseases and surgical procedures further drives market growth. Additionally, initiatives aimed at improving patient outcomes and reducing transfusion-related complications are significant catalysts for demand. The United States is the leading country in this market, with key players like Haemonetics, Baxter International, and Cerus Corporation dominating the landscape. The competitive environment is characterized by continuous innovation and strategic partnerships among these companies. Canada also plays a vital role, contributing to the market with its robust healthcare system and increasing adoption of blood management technologies. ### Europe : Emerging Market with Growth Potential Europe is the second-largest market for Patient Blood Management Market, accounting for approximately 30% of the global share. The region is witnessing a growing demand for effective blood management solutions driven by an aging population and increasing surgical procedures. Regulatory support from the European Medicines Agency (EMA) and national health authorities is fostering innovation and adoption of new technologies in blood management, enhancing patient safety and care. Leading countries in this region include Germany, France, and the UK, where major players like Fresenius Kabi and Grifols are actively involved. The competitive landscape is marked by collaborations and mergers aimed at expanding product offerings and market reach. The presence of advanced healthcare facilities and a focus on improving transfusion practices further bolster the market's growth potential. ### Asia-Pacific : Rapidly Growing Market Segment Asia-Pacific is an emerging powerhouse in the Patient Blood Management Market, holding about 20% of the global share. The region's growth is fueled by increasing healthcare expenditures, rising awareness of blood management practices, and a growing population. Countries like China and India are witnessing significant investments in healthcare infrastructure, which is expected to enhance the adoption of blood management solutions. Additionally, government initiatives aimed at improving healthcare access are acting as catalysts for market growth. China is the largest market in this region, followed by India and Japan. The competitive landscape features key players such as Terumo Corporation and Medtronic, who are focusing on expanding their presence through strategic partnerships and local collaborations. The increasing prevalence of [chronic](https://www.marketresearchfuture.com/reports/chronic-disease-management-market-981)diseases and surgical procedures in these countries is further driving the demand for effective blood management solutions. ### Middle East and Africa : Untapped Market with Opportunities The Middle East and Africa represent a developing market for Patient Blood Management Market, holding around 5% of the global share. The region is characterized by a growing demand for healthcare services, driven by increasing population and rising incidences of chronic diseases. Regulatory bodies are beginning to implement frameworks that support the adoption of advanced blood management technologies, which is expected to enhance patient care and safety in the coming years. Countries like South Africa and the UAE are leading the market, with a focus on improving healthcare infrastructure and access to blood management solutions. The competitive landscape is gradually evolving, with both local and international players entering the market. Key players are exploring partnerships and collaborations to expand their reach and enhance service delivery in this region, which presents significant growth opportunities. .webp ## Competitive Benchmarking The Patient Blood Management Market is currently characterized by a dynamic competitive landscape, driven by a confluence of technological advancements, regulatory changes, and an increasing emphasis on patient safety. Key players such as Haemonetics (US), Terumo Corporation (JP), and Fresenius Kabi (DE) are strategically positioned to leverage these trends. Haemonetics (US) focuses on innovation in blood management solutions, particularly through the development of advanced blood collection and processing technologies. Terumo Corporation (JP) emphasizes regional expansion and partnerships, enhancing its global footprint in the blood management sector.   Meanwhile, Fresenius Kabi (DE) is concentrating on digital transformation initiatives to optimize its product offerings and improve operational efficiencies. Collectively, these strategies contribute to a competitive environment that is increasingly centered on technological innovation and patient-centric solutions.In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance responsiveness to market demands.   The Patient Blood Management Market appears moderately fragmented, with a mix of established players and emerging companies vying for market share. The collective influence of these key players shapes the market structure, as they engage in strategic collaborations and investments to bolster their competitive positions.   In August 2025, Haemonetics (US) announced the launch of a new blood management software platform designed to streamline hospital operations and improve patient outcomes. This strategic move is likely to enhance their product portfolio and solidify their position as a leader in the market, as hospitals increasingly seek integrated solutions that improve efficiency and safety.   In September 2025, Terumo Corporation (JP) entered into a partnership with a leading healthcare technology firm to develop AI-driven blood management systems. This collaboration is indicative of a broader trend towards the integration of artificial intelligence in healthcare, suggesting that Terumo is positioning itself at the forefront of technological innovation in blood management.   In July 2025, Fresenius Kabi (DE) expanded its manufacturing capabilities in Europe, focusing on the production of blood components and transfusion solutions. This expansion not only enhances their supply chain reliability but also reflects a strategic response to the growing demand for blood management products in the region, potentially increasing their market share.   As of October 2025, the Patient Blood Management Market is witnessing significant trends such as digitalization, sustainability, and the integration of artificial intelligence. Strategic alliances among key players are shaping the competitive landscape, fostering innovation and enhancing operational efficiencies. Looking ahead, it appears that competitive differentiation will increasingly hinge on technological advancements and supply chain reliability, moving away from traditional price-based competition. Companies that prioritize innovation and patient-centric solutions are likely to emerge as leaders in this evolving market..webp ## Recent News & Developments _**September 2022:**A long-term agreement was inked by Canadian Blood Services, Canada's national blood authority, and Grifols, a major participant in the world of plasma pharmaceuticals. This arrangement would enable the company to greatly boost Canada's self-sufficiency in immunoglobulin (Ig) medications, important plasma-protein therapies used to treat a variety of immunodeficiencies as well as other health issues._ _**April 2022:**In order to do additional research on freeze-dried plasma (FDP), Terumo Blood and Cell Technologies was given a contract worth USD 10.6 million. The Defense Health Agency (DHA) sponsors the contract, which is managed by the Naval Medical Research Centre (NMRC). It is with MTEC, a 501(c)(3) biomedical technology consortium that collaborates with the U.S. Army Medical Research and Development Command under an Other Transaction Agreement (OTA)._ ## Report Scope | MARKET SIZE 2024 | 8.61(USD Billion) | | --- | --- | | MARKET SIZE 2025 | 9.15(USD Billion) | | MARKET SIZE 2035 | 16.81(USD Billion) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.27% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Billion | | Key Companies Profiled | Haemonetics (US), Terumo Corporation (JP), Fresenius Kabi (DE), Grifols (ES), Baxter International (US), Cerus Corporation (US), BloodCenter of Wisconsin (US), Octapharma (CH), Medtronic (US) | | Segments Covered | Product, Component, End-User, Region | | Key Market Opportunities | Integration of advanced data analytics to optimize blood utilization and enhance patient outcomes in the Patient Blood Management Market. | | Key Market Dynamics | Rising emphasis on patient safety drives innovation and regulatory changes in the Patient Blood Management Market. | | Countries Covered | North America, Europe, APAC, South America, MEA | ## Frequently Asked Questions **Q: What is the current valuation of the Patient Blood Management Market?** A: The Patient Blood Management Market was valued at 8.61 USD Billion in 2024. **Q: What is the projected market size for the Patient Blood Management Market by 2035?** A: The market is projected to reach 16.81 USD Billion by 2035. **Q: What is the expected CAGR for the Patient Blood Management Market during the forecast period 2025 - 2035?** A: The expected CAGR for the market during this period is 6.27%. **Q: Which companies are considered key players in the Patient Blood Management Market?** A: Key players include Haemonetics, Terumo Corporation, Fresenius Kabi, Grifols, Baxter International, Cerus Corporation, BloodCenter of Wisconsin, Octapharma, and Medtronic. **Q: What are the main product segments in the Patient Blood Management Market?** A: Main product segments include Instruments, Accessories, Reagents and Kits, and Software. **Q: How much is the Instruments segment projected to grow by 2035?** A: The Instruments segment is projected to grow from 2.58 USD Billion in 2024 to 5.18 USD Billion by 2035. **Q: What is the expected growth for the Plasma component in the Patient Blood Management Market?** A: The Plasma component is expected to increase from 5.16 USD Billion in 2024 to 10.0 USD Billion by 2035. **Q: Which end-user segments are included in the Patient Blood Management Market?** A: End-user segments include Blood Banks, Hospitals, Diagnostic Clinics, and Pathology Labs. **Q: What is the projected growth for the Hospitals segment by 2035?** A: The Hospitals segment is projected to grow from 4.3 USD Billion in 2024 to 8.6 USD Billion by 2035. **Q: How does the market's growth potential compare across different segments?** A: The market's growth potential varies, with the Software segment expected to rise from 2.16 USD Billion in 2024 to 3.74 USD Billion by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/patient-blood-management-market-8798*